trial · primary record
BNT113
Unresectable Head and Neck Squamous Cell Carcinoma
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | ACTIVE |
| Sponsor | Unknown |
| Enrolment | 358 |
| Primary completion | 2029-04 |
| Primary endpoint | Part A - Occurrence of treatment-emergent adverse event (TEAE) - BNT113 in combination with pembrolizumab |
| Registry ID | NCT04534205 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:38:06.716Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT04534205
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.